It’s traditional to end the year with a look back at what you hoped to accomplish and an assessment of what you did. By that standard 2016 has been a pretty good year for us at CIRM. Yesterday our governing Board approved funding for two new clinical trials, one to help kidney transplant patients, the … Continue reading California’s stem cell agency rounds up the year with two more big hits
C. Randal Mills
Stem cell agency funds clinical trials in three life-threatening conditions
A year ago the CIRM Board unanimously approved a new Strategic Plan for the stem cell agency. In the plan are some rather ambitious goals, including funding ten new clinical trials in 2016. For much of the last year that has looked very ambitious indeed. But today the Board took a big step towards reaching … Continue reading Stem cell agency funds clinical trials in three life-threatening conditions
Creating a “Pitching Machine” to speed up our delivery of stem cell treatments to patients
When baseball players are trying to improve their hitting they’ll use a pitching machine to help them fine tune their stroke. Having a device that delivers a ball at a consistent speed can help a batter be more consistent and effective in their swing, and hopefully get more hits. That’s what we are hoping our … Continue reading Creating a “Pitching Machine” to speed up our delivery of stem cell treatments to patients
CIRM and QuintilesIMS Kick Off Accelerating Center to Help Stem Cell Therapies Soar
You wouldn’t ask a goldfish to take flying lessons, right? The chances of success would be slim. But in essence, that’s the predicament in which CIRM has found itself when asking top notch stem cell scientists to use the agency’s funding to carry their great cell therapy ideas into and through clinical trials. While these … Continue reading CIRM and QuintilesIMS Kick Off Accelerating Center to Help Stem Cell Therapies Soar
Funding stem cell research targeting a rare and life-threatening disease in children
If you have never heard of cystinosis you should consider yourself fortunate. It’s a rare condition caused by an inherited genetic mutation. It hits early and it hits hard. Children with cystinosis are usually diagnosed before age 2 and are in end-stage kidney failure by the time they are 9. If that’s not bad enough … Continue reading Funding stem cell research targeting a rare and life-threatening disease in children
CIRM’s Randy Mills: New FDA rules for stem cells won’t fix the problem
For the last two days the Food and Drug Administration (FDA) has been holding a hearing in Bethesda, Maryland on new regulations that would tighten control over stem cell treatments. The FDA invited public testimony during the hearing on the regulations that would impact many of the clinics that currently offer unproven therapies The testimony … Continue reading CIRM’s Randy Mills: New FDA rules for stem cells won’t fix the problem
Young man with spinal cord injury regains use of hands and arms after stem cell therapy
Hope is such a fragile thing. We cling to it in bad times. It offers us a sense that we can bear whatever hardships we are facing today, and that tomorrow will be better. Kris Boesen knows all about holding on to hope during bad times. On March 6th of this year he was left … Continue reading Young man with spinal cord injury regains use of hands and arms after stem cell therapy
Clearing the first hurdle: spinal cord injury trial passes safety review
Starting a clinical trial is like taking a step into the unknown. It’s moving a potential therapy out of the lab and testing it in people. To reach this point the researchers have done a lot of work trying to ensure the therapy is safe. But that work was done in the lab, and on … Continue reading Clearing the first hurdle: spinal cord injury trial passes safety review
A look back at the last year – but with our eyes firmly on the future
Better. With that single word Randy Mills, our President and CEO, starts and ends his letter in our 2015 Annual Report and lays out the simple principle that guides the way we work at CIRM. Better. But better what? “Better infrastructure to translate early stage ideas into groundbreaking clinical trials. Better regulatory practices to advance … Continue reading A look back at the last year – but with our eyes firmly on the future
Accelerating the drive for new stem cell treatments
Acceleration is defined as the “increase in the rate or speed of something.” For us that “something” is new stem cell treatments for patients with unmet medical needs. Today our governing Board just approved a $15 million partnership with Quintiles to help us achieve that acceleration. Quintiles was awarded the funding to create a new … Continue reading Accelerating the drive for new stem cell treatments
The Stem Cellar 